Review article
Cardiotoxicity of Anthracyclines – an Unsolved Problem
Dtsch Arztebl 2006; 103(37): A-2393
;
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
| 1. | Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM: Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60: 1213–8. MEDLINE |
| 2. | Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302–14. MEDLINE |
| 3. | Von Hoff DD, Layard MW, Basa P et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7. MEDLINE |
| 4. | Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–79. MEDLINE |
| 5. | Speyer JL, Green MD, Zeleniuch-Jacquotte A et al.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117–27. MEDLINE |
| 6. | Tjeerdsma G, Meinardi MT, van der Graaf WTA et al.: Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419–23. MEDLINE |
| 7. | Jensen BV, Skovsgaard T, Nielsen SL: Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699–709. MEDLINE |
| 8. | Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Jama 1991; 266: 1672–7. MEDLINE |
| 9. | Henderson IC, Allegra JC, Woodcock T et al.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560–71. MEDLINE |
| 10. | Wojnowski L, Kulle B, Schirmer M et al.: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754–62. MEDLINE |
| 11. | Zucchi R, Danesi R: Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anti-Canc Agents 2003; 3: 151–71. MEDLINE |
| 12. | Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229. MEDLINE |
| 13. | Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE: Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561–78. MEDLINE |
| 14. | Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabro R: Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 2005; 7: 67–76. MEDLINE |
| 15. | Legha SS, Benjamin RS, Mackay B et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9. MEDLINE |
| 16. | Shapira J, Gotfried M, Lishner M, Ravid M:. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990; 65: 870–3. MEDLINE |
| 17. | Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M: Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41: 431–44. MEDLINE |
| 18. | Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S: Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiovasc Pharmacol 2000; 35: 100–8. MEDLINE |
| 19. | Bos AM, de Vries EG, Dombernovsky P et al.: Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother Pharmacol 2001; 48: 361–9. MEDLINE |
| 20. | Schrijvers D, Bos AM, Dyck J et al.: Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann Oncol 2002; 13: 385–91. MEDLINE |
| 21. | Singal PK, Iliskovic N, Li T, Kumar D: Adriamycin cardiomyopathy: pathophysiology and prevention. Faseb J 1997; 11: 931–6. MEDLINE |
| 22. | Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N: Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207: 77–86. MEDLINE |
| 23. | van Dalen EC, Caron HN, Dickinson HO, Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005: CD003917. MEDLINE |
| 24. | Cvetkovic RS, Scott LJ:. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005; 65: 1005–24. MEDLINE |
| Literatur Internet | |
| e1. | Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA: Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191–6. MEDLINE |
| e2. | Green DM, Grigoriev YA, Nan B et al.: Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19: 1926–34. MEDLINE |
| e3. | Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–15. MEDLINE |
| e4. | Pinkel D, Camitta B, Kun L, Howarth C, Tang T: Doxorubicin cardiomyopathy in children with left-sided Wilms tumor. Med Pediatr Oncol 1982; 10: 483–8. MEDLINE |
| e5. | Grenier MA, Lipshultz SE: Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25: 72–85. MEDLINE |
| e6. | Lipshultz SE, Lipsitz SR, Sallan SE et al.: Long-Term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517–22. MEDLINE |
| e7. | Forrest GL, Gonzalez B, Tseng W, Li X, Mann J: Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 2000; 60: 5158–64. MEDLINE |
| e8. | Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH: Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 2003; 63: 6602–6. MEDLINE |
| e9. | Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727–41. MEDLINE |
| e10. | Olson RD, Mushlin PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. Faseb J 1990; 4: 3076–86. MEDLINE |
| e11. | Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G: Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001; 52: 83–8. MEDLINE |
| e12. | Bleyer WA: The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990; 40: 355–67. MEDLINE |
| e13. | Hortobagyi GN: Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54 (Suppl.) 4: 1–7. MEDLINE |
| e14. | Berrak SG, Ewer MS, Jaffe N et al.: Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001; 8: 611–4. MEDLINE |
| e15. | Lipshultz SE, Giantris AL, Lipsitz SR et al.: Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 2002; 20: 1677–82 MEDLINE . |
| e16. | Gupta M, Steinherz PG, Cheung NK, Steinherz L: Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 2003; 40: 343–7. MEDLINE |
| e17. | Levitt GA, Dorup I, Sorensen K, Sullivan I: Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 2004;124:463–8 MEDLINE . |
| e18. | Gabizon A, Shmeeda H, Barenholz Y: Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419–36. MEDLINE |
| e19. | Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691–743. MEDLINE |
| e20. | Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P: Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3502–8. MEDLINE |
| e21. | Borchmann P, Hubel K, Schnell R, Engert A: Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80–3. MEDLINE |
| e22. | Anderlini P, Benjamin RS, Wong FC et al.: Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827–34. MEDLINE |
| e23. | Cottin Y, Touzery C, Dalloz F et al.: Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998; 21: 665–70. MEDLINE |
| e24. | Stohr W, Paulides M, Brecht I et al.: Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS). J Cancer Res Clin Oncol 2006; 132: 35–40. MEDLINE |
| e25. | Burton C, Smith P, Vaughan-Hudson G et al.: Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Br J Haematol 2005; 130: 536–41 MEDLINE . |
| e26. | Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E: Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 1991; 46: 301–5. MEDLINE |
| e27. | Zinzani PL, Martelli M, Storti S et al.: Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995; 19: 329–35. MEDLINE |
| e28. | Wong BK, DeFeo-Jones D, Jones RE et al.: PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 2001; 29: 313–8. MEDLINE |
| e29. | DiPaola RS, Rinehart J, Nemunaitis J et al.: Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002; 20: 1874–9. MEDLINE |
| e30. | Broker LE, Giaccone G: The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer 2002; 38: 2347–61. MEDLINE |
| e31. | Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA: Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414: 71–8. MEDLINE |
| e32. | Santos JM, Luna Filho B, Simoes MJ, et al.: Effect of enalaprilat on cardiotoxicity induced by doxorubicin. Arq Bras Cardiol 1996; 67: 237–41. MEDLINE |
| e33. | Okumura K, Jin D, Takai S, Miyazaki M: Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002; 88: 183–8. MEDLINE |
| e34. | Boucek RJ, Jr., Steele A, Miracle A, Atkinson J: Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 2003; 3: 319–29. MEDLINE |
| e35. | Vaynblat M, Shah HR, Bhaskaran D et al.: Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002; 4: 583–6. MEDLINE |
| e36. | Fujita N, Hiroe M, Ohta Y, Horie T, Hosoda S: Chronic effects of metoprolol on myocardial beta-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol 1991; 17: 656–61. MEDLINE |
| e37. | Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T: Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999; 65: 1265–74. MEDLINE |
| e38. | Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB: Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002; 185: 218–27. MEDLINE |
| e39. | Thomas L, Bellmont S, Christen MO, La Roche B, Monassier L: Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. Fundam Clin Pharmacol 2004; 18: 649–55. MEDLINE |
| e40. | Oliveira PJ, Bjork JA, Santos MS et al.: Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 2004; 200: 159–68. MEDLINE |
| e41. | Seymour L, Bramwell V, Moran LA: Use of dexrazoxan as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer: the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999; 3: 145–59. MEDLINE |
